Sowell Financial Services LLC Buys 341,889 Shares of SOPHiA GENETICS SA $SOPH

Sowell Financial Services LLC purchased a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 341,889 shares of the company’s stock, valued at approximately $2,865,000. Sowell Financial Services LLC owned 0.41% of SOPHiA GENETICS at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. increased its holdings in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at about $50,000. 1492 Capital Management LLC raised its position in shares of SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after buying an additional 17,406 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after buying an additional 18,781 shares during the period. Finally, AXQ Capital LP bought a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $119,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total transaction of $61,710.00. Following the completion of the transaction, the chairman owned 3,387,150 shares in the company, valued at $24,590,709. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $7.26, for a total value of $36,300.00. Following the sale, the insider directly owned 195,993 shares in the company, valued at $1,422,909.18. The trade was a 2.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 255,662 shares of company stock worth $1,970,799 in the last 90 days. 4.88% of the stock is currently owned by insiders.

SOPHiA GENETICS Stock Up 6.1%

SOPH opened at $7.35 on Thursday. SOPHiA GENETICS SA has a fifty-two week low of $3.75 and a fifty-two week high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The firm’s fifty day moving average price is $7.92 and its two-hundred day moving average price is $6.29. The company has a market capitalization of $616.63 million, a P/E ratio of -6.39 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SOPH. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a report on Monday, October 12th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.